Kiuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M, Glaucoma Guideline Preparation Committee, Japan Glaucoma Society. The Japan Glaucoma Society guidelines for glaucoma, 5th edition. Jpn J Ophthalmol. 2023;67:189-254.

Inoue K, Shiokawa M, Higa R, Sugahara M, Soga T, Wakakura, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye (Lond). 2012;26:1465–72. https://doi.org/10.1038/eye.2012.195.

Article  CAS  PubMed  Google Scholar 

Inoue K, Shiokawa M, Wakakura M, Tomita G. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013;22:626–31.

Article  PubMed  Google Scholar 

Aihara M, Fenghe Lu, Kawata H, Iwata A, Liu K, Odani-Kawabata N, et al. Phase 2, randomized, dose-finding studies of Omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension. J Glaucoma. 2019;28:375–85. https://doi.org/10.1097/IJG.0000000000001221.

Article  PubMed  Google Scholar 

Aihara M, Lu F, Kamata H, Iwata A, Odani-Kawabata N, Shams NK. Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: The Phase 3 AYAME Study. Am J Ophthalmol. 2020;220:53–62.

Article  CAS  PubMed  Google Scholar 

Olander KW, Sato MA, Abrams MA, Jerkins GW, Lu F, Dinh P, et al. A randomized phase 2 trial comparing Omidenepag isopropyl 0.002% once and twice daily in subjects with primary open-angle glaucoma or ocular hypertension (SPECTRUM-6). J Glaucoma. 2021;30:473–80.

Article  PubMed  PubMed Central  Google Scholar 

Aihara M, Ropo A, Lu F, Kawata H, Iwata A, Odani-Kawabata N, et al. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study. Jpn J Ophthalmol. 2020;64:398–406.

Article  CAS  PubMed  Google Scholar 

Inoue K, Shiokawa M, Katakura S, Shimizu K, Ishida K, Tomita G. Periocular adverse reactions to omidenepag isopropyl. Am J Ophthalmol. 2022;237:114–21.

Article  CAS  PubMed  Google Scholar 

Sakata R, Fujishiro T, Saito H, Nakamura N, Honjo M, Shirato S, et al. Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis. Jpn J Ophthalmol. 2021;65:591–7.

Article  CAS  PubMed  Google Scholar 

Inoue K, Shiokawa M, Kunimatsu-Sanuki S, Nozaki N, Shimizu K, Ishida K, et al. One-year efficacy and safety of omidenepag isopropyl in patients with normal-tension glaucoma. J Ocul Pharmacol Ther. 2022;38:354–8.

Article  CAS  PubMed  Google Scholar 

Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N. Twelve-month efficacy of omidenepag isopropyl, a selective ER2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. Jpn J Ophthalmol. 2021;65:810–9.

Article  CAS  PubMed  Google Scholar 

Nakazawa T, Takahashi K, Kuwayama Y, Nomura A, Shimada F. Interim results of post-marketing observational study of omidenepag isopropyl for glaucoma and ocular hypertension in Japan. Adv Ther. 2022;39:1359–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ozaki H, Kobayashi S, Yokoo Y, Nozaki N, Shimizu K, Ishida K. One-year outcome of omidenepag isopropyl in primary open angle glaucoma and preperimetric glaucoma. Rinsho Ganka. 2022;76:1380–6 (in Japanese).

Google Scholar 

Chikaraishi Y, Arakaki Y, Koizumi H. Evaluation of the long-term safety and efficacy of omidenepag isopropyl ophthalmic solution. Atarashii Ganka. 2022;39:1530–3 (in Japanese).

CAS  Google Scholar 

Kozaki J, Maeda N, Kosaki R. Efficacy and safety of selective prostaglandin EP2 agonist in primary open angle glaucoma and ocular hypertension. Rinsho Ganka. 2022;76:85–92 (in Japanese).

Google Scholar 

Kikuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M. The Japan Glaucoma Society guidelines for glaucoma 5th edition. Jpn J Ophthalmol. 2023;67:189–254.

Article  Google Scholar 

Inoue K, Shiokawa M, Fujimoto T, Tomita G. Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma. Clin Ophthalmol. 2014;8:1179–83.

Article  PubMed  PubMed Central  Google Scholar 

Inoue K, Tanaka A, Tomita G. Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma. Clin Ophthalmol. 2013;7:1411–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inoue K, Iwasa M, Wakakura M, Tomita G. Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma. Clin Ophthalmol. 2012;6:1315–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takemoto D, Higashide T, Saito Y, Ohkubo S, Udagawa S, Takeda H, et al. Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study. Clin Ophthalmol. 2017;11:1617–24.

Article  CAS  PubMed  PubMed Central  Google Scholar